PMC:7600245 / 31918-32251 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T119","span":{"begin":52,"end":60},"obj":"Disease"}],"attributes":[{"id":"A119","pred":"mondo_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Recently, a small, randomized study in hospitalized COVID-19 adults (n = 22) in China compared lopinavir/ritonavir (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days) against chloroquine (500 mg twice daily for 10 days) and found that chloroquine was linked to a shorter time to RT-PCR conversion and a faster recovery [100]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T290","span":{"begin":10,"end":11},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T291","span":{"begin":69,"end":75},"obj":"http://purl.obolibrary.org/obo/CLO_0007926"},{"id":"T292","span":{"begin":269,"end":270},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T293","span":{"begin":309,"end":310},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Recently, a small, randomized study in hospitalized COVID-19 adults (n = 22) in China compared lopinavir/ritonavir (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days) against chloroquine (500 mg twice daily for 10 days) and found that chloroquine was linked to a shorter time to RT-PCR conversion and a faster recovery [100]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T466","span":{"begin":95,"end":114},"obj":"Chemical"},{"id":"T467","span":{"begin":95,"end":104},"obj":"Chemical"},{"id":"T468","span":{"begin":105,"end":114},"obj":"Chemical"},{"id":"T469","span":{"begin":116,"end":125},"obj":"Chemical"},{"id":"T470","span":{"begin":133,"end":142},"obj":"Chemical"},{"id":"T471","span":{"begin":183,"end":194},"obj":"Chemical"},{"id":"T472","span":{"begin":243,"end":254},"obj":"Chemical"}],"attributes":[{"id":"A466","pred":"chebi_id","subj":"T466","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A467","pred":"chebi_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A468","pred":"chebi_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A469","pred":"chebi_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A470","pred":"chebi_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A471","pred":"chebi_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A472","pred":"chebi_id","subj":"T472","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"Recently, a small, randomized study in hospitalized COVID-19 adults (n = 22) in China compared lopinavir/ritonavir (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days) against chloroquine (500 mg twice daily for 10 days) and found that chloroquine was linked to a shorter time to RT-PCR conversion and a faster recovery [100]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T232","span":{"begin":0,"end":333},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recently, a small, randomized study in hospitalized COVID-19 adults (n = 22) in China compared lopinavir/ritonavir (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days) against chloroquine (500 mg twice daily for 10 days) and found that chloroquine was linked to a shorter time to RT-PCR conversion and a faster recovery [100]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"911","span":{"begin":95,"end":114},"obj":"Chemical"},{"id":"912","span":{"begin":116,"end":125},"obj":"Chemical"},{"id":"913","span":{"begin":133,"end":142},"obj":"Chemical"},{"id":"914","span":{"begin":183,"end":194},"obj":"Chemical"},{"id":"915","span":{"begin":243,"end":254},"obj":"Chemical"},{"id":"921","span":{"begin":52,"end":60},"obj":"Disease"}],"attributes":[{"id":"A911","pred":"tao:has_database_id","subj":"911","obj":"MESH:C558899"},{"id":"A912","pred":"tao:has_database_id","subj":"912","obj":"MESH:D061466"},{"id":"A913","pred":"tao:has_database_id","subj":"913","obj":"MESH:D019438"},{"id":"A914","pred":"tao:has_database_id","subj":"914","obj":"MESH:D002738"},{"id":"A915","pred":"tao:has_database_id","subj":"915","obj":"MESH:D002738"},{"id":"A921","pred":"tao:has_database_id","subj":"921","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Recently, a small, randomized study in hospitalized COVID-19 adults (n = 22) in China compared lopinavir/ritonavir (lopinavir 400 mg/ritonavir 100 mg twice daily for 10 days) against chloroquine (500 mg twice daily for 10 days) and found that chloroquine was linked to a shorter time to RT-PCR conversion and a faster recovery [100]."}